# Group 3: Mitochondrial Therapies

> **Data Source Note:** Compiled from training knowledge through May 2025. Items marked [VERIFY] would benefit from live search confirmation.

---

## 3.1 Urolithin A (Amazentis/Timeline)

### Mechanism of Action

Urolithin A (UA) is a natural gut microbiome-derived metabolite produced from ellagitannins and ellagic acid found in pomegranates, berries, and nuts. Only ~40% of the population produces UA endogenously due to microbiome variability, making supplementation relevant.

**Detailed mechanism -- mitophagy activation:**

1. **Mitophagy induction:** UA is the most potent natural mitophagy activator identified. It activates PINK1/Parkin-dependent mitophagy:
   - UA causes a mild mitochondrial stress (reduction in mitochondrial membrane potential)
   - PINK1 accumulates on damaged/dysfunctional mitochondria
   - PINK1 phosphorylates ubiquitin and recruits Parkin (E3 ubiquitin ligase)
   - Parkin ubiquitinates outer mitochondrial membrane proteins
   - Ubiquitinated mitochondria are recognized by autophagy receptors (p62/SQSTM1, OPTN, NDP52)
   - Autophagosomes engulf and deliver damaged mitochondria to lysosomes for degradation

2. **Mitochondrial biogenesis:** Following mitophagy-mediated clearance of dysfunctional mitochondria, UA upregulates:
   - PGC-1alpha (master regulator of mitochondrial biogenesis)
   - TFAM (mitochondrial transcription factor A)
   - NRF1/NRF2 (nuclear respiratory factors)
   - Result: New, functional mitochondria replace old, damaged ones

3. **Net effect:** Improved mitochondrial quality control -- removal of defective mitochondria + replacement with new functional ones = improved cellular energy production, reduced ROS, improved metabolic function.

4. **Additional pathways:**
   - AMPK activation (energy-sensing, overlaps with metformin)
   - SIRT1/SIRT3 activation (via improved NAD+ utilization)
   - Anti-inflammatory effects (reduced IL-6, TNF-alpha; NF-kB suppression)
   - Improved muscle stem cell function (via better mitochondrial health)

### Key Preclinical Results

| Study | Species | Key Finding | Reference |
|-------|---------|-------------|-----------|
| Ryu et al. 2016 | C. elegans + Mouse | UA extended C. elegans lifespan by ~45%; improved exercise capacity in aged mice by ~42%; enhanced mitophagy in both species | Ryu D, et al. Nat Med. 2016;22(8):879-888. DOI: 10.1038/nm.4132 |
| Andreux et al. 2019 | Human (Phase 1) | First-in-human study: UA (250mg, 500mg, 1000mg, 2000mg) was safe and bioavailable; induced mitophagy biomarkers in skeletal muscle at 500mg+ | Andreux PA, et al. Nat Metab. 2019;1(6):595-603. DOI: 10.1038/s42255-019-0073-4 |
| Luan et al. 2021 | Mouse | UA improved muscle strength and endurance in aged mice; reduced age-related muscle atrophy; enhanced satellite cell function | Luan P, et al. Cell Metab. 2021 [VERIFY exact citation] |
| D'Amico et al. 2021 | C. elegans + Mouse | UA improved intestinal barrier function and reduced age-related gut inflammation | D'Amico D, et al. Nat Aging. 2021;1(12):1116-1126 |

**Lifespan data:**
- C. elegans: ~45% lifespan extension (Ryu et al. 2016) -- one of the largest effects seen with a natural compound
- Mouse lifespan study: Not formally published for maximum lifespan; most mouse studies focus on healthspan (muscle function, exercise capacity) [VERIFY if lifespan data published 2024-2025]

### Clinical Trial Status (as of early 2025)

| NCT Number | Phase | Population | Status | Key Details |
|------------|-------|------------|--------|-------------|
| NCT03283462 | Phase 1 | Healthy elderly (60-80 yrs) | Completed | Andreux et al. 2019; UA 250-2000mg; safe, bioavailable, mitophagy biomarkers improved |
| NCT03464500 | Phase 2 (ATLAS) | Elderly with declining muscle function | Completed | UA 500mg and 1000mg daily x 4 months; improved mitochondrial biomarkers; presented at multiple conferences |
| NCT04160312 | Phase 2 | Middle-aged overweight adults | Completed | UA (Mitopure) 500mg and 1000mg; 4 months; improved mitochondrial function, muscle endurance |
| NCT04783207 | Phase 3 [VERIFY] | Older adults with muscle function decline | Active [VERIFY] | Larger confirmatory study |
| NCT05735886 | Phase 2 [VERIFY] | Cognitive function in older adults | Recruiting [VERIFY] | UA for brain mitochondrial function |
| NCT05921344 | N/A | Healthy adults, exercise capacity | Active [VERIFY] | UA + exercise combination |

**Key clinical results (ATLAS and follow-up studies):**

- **ATLAS trial (Liu et al. 2022):**
  - 66 elderly participants (65-90 years) with declining muscle function
  - UA (Mitopure) 500mg or 1000mg daily vs. placebo for 4 months
  - **Results:**
    - Significant improvement in muscle endurance (6-min walk test improvement)
    - Improved hand grip strength (1000mg group)
    - Increased plasma acylcarnitines (biomarker of improved mitochondrial fatty acid oxidation)
    - Improved mitochondrial gene expression in muscle biopsies
    - Reduced plasma CRP (inflammatory marker)
    - Well-tolerated; no significant safety signals
  - Published: Liu S, D'Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. *JAMA Netw Open*. 2022;5(1):e2144279. DOI: 10.1001/jamanetworkopen.2021.44279

- **Singh et al. 2022 (middle-aged adults):**
  - 88 overweight, middle-aged adults
  - UA 500mg or 1000mg daily x 4 months
  - Improved plasma acylcarnitines, improved muscle mitochondrial efficiency
  - Published: Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. *Cell Rep Med*. 2022;3(5):100633. DOI: 10.1016/j.xcrm.2022.100633

### 2023-2025 Developments

- **Timeline (Amazentis/Nestle Health Science):** Timeline is the commercial brand of Mitopure (standardized UA supplement), developed by Amazentis, which partnered with Nestle Health Science
  - Available as consumer supplement (Mitopure) in multiple formulations
  - Pricing: ~$45-60/month for 500mg daily dose
  - Marketed for muscle health, energy, and "cellular nutrition"

- **Expanded clinical program:** Additional trials in cognitive function, joint health, and exercise performance were registered 2023-2024 [VERIFY specific NCTs]

- **Mechanistic publications:** Multiple 2023-2024 papers further elucidating UA's mechanism, including effects on:
  - Gut-muscle axis communication
  - Immune cell mitochondrial function
  - Epigenetic aging markers (preliminary data suggesting UA may slow epigenetic aging) [VERIFY]

- **Regulatory status:** UA is marketed as a dietary supplement (not a drug) in the US and EU. The company has pursued the supplement route rather than the pharmaceutical pathway, allowing faster market access but limiting health claims.

### Safety/Adverse Event Profile

- **Very well-tolerated** across all clinical studies
- No serious adverse events attributed to UA at doses up to 2000mg/day (acute) or 1000mg/day (chronic 4 months)
- Most common AEs: Mild GI symptoms (comparable to placebo in most trials)
- No hepatotoxicity, nephrotoxicity, or hematological abnormalities
- UA has been granted GRAS (Generally Recognized as Safe) status by the FDA
- Long-term safety data (>12 months) is still limited but accumulating

### Key Publications

1. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. *Nat Med*. 2016;22(8):879-888. DOI: 10.1038/nm.4132
2. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat Metab*. 2019;1(6):595-603. DOI: 10.1038/s42255-019-0073-4
3. Liu S, D'Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. *JAMA Netw Open*. 2022;5(1):e2144279. DOI: 10.1001/jamanetworkopen.2021.44279
4. Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. *Cell Rep Med*. 2022;3(5):100633. DOI: 10.1016/j.xcrm.2022.100633

### Controversies

- **Modest clinical effect sizes:** While statistically significant, the improvements in muscle function and endurance are modest. Critics argue these could be achieved with exercise alone.
- **Supplement vs. drug path:** By choosing the supplement route, Amazentis avoids rigorous Phase 3 trials; this limits the strength of evidence.
- **Microbiome confounding:** Natural UA producers may derive less benefit from supplementation; individual variation is high.
- **No human lifespan data:** All longevity claims are extrapolated from C. elegans and rodent healthspan data.

---

## 3.2 SS-31 / Elamipretide (Stealth BioTherapeutics)

### Mechanism of Action

SS-31 (also known as elamipretide, Bendavia, MTP-131) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Stealth BioTherapeutics.

**Detailed mechanism:**

1. **Mitochondrial inner membrane targeting:** SS-31 is a cell-permeable peptide that concentrates >1000-fold in mitochondria due to its positive charge and lipophilicity. It selectively binds to cardiolipin on the inner mitochondrial membrane.

2. **Cardiolipin interaction:** Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It is essential for:
   - Electron transport chain (ETC) complex assembly and supercomplex formation
   - Cytochrome c anchoring to the inner membrane
   - ATP synthase function
   - Mitochondrial dynamics (fission/fusion)

3. **Age-related cardiolipin changes:** With aging, cardiolipin:
   - Undergoes oxidative damage (peroxidation)
   - Decreases in total content
   - Changes in acyl chain composition
   - This disrupts ETC function, increases ROS production, and impairs ATP synthesis

4. **SS-31's protective effects:**
   - Stabilizes cardiolipin structure and prevents peroxidation
   - Improves ETC supercomplex assembly and electron transfer efficiency
   - Reduces electron leak and ROS production at complexes I and III
   - Improves ATP synthesis efficiency
   - Prevents cytochrome c detachment (reducing apoptosis trigger)
   - Improves mitochondrial coupling (reduces proton leak)

5. **Downstream benefits:**
   - Improved cellular energetics
   - Reduced oxidative stress
   - Improved organ function (heart, kidney, brain, skeletal muscle)
   - Reduced inflammation (via reduced mitochondrial damage signals)

### Key Preclinical Results

| Study | Species | Key Finding | Reference |
|-------|---------|-------------|-----------|
| Siegel et al. 2013 | Mouse | SS-31 improved cardiac function in aged mice; restored mitochondrial ultrastructure; improved ETC complex activity | Siegel MP, et al. Aging Cell. 2013;12(5):763-71. DOI: 10.1111/acel.12097 |
| Campbell et al. 2019 | Mouse | SS-31 reversed age-related decline in skeletal muscle mitochondrial function; improved exercise capacity and reduced fatigue | Campbell MD, et al. Aging Cell. 2019;18(3):e12951. DOI: 10.1111/acel.12951 |
| Sweetwyne et al. 2017 | Mouse | 8 weeks SS-31 in aged mice reversed age-related changes in kidney mitochondria; improved renal function; reduced glomerulosclerosis | Sweetwyne MT, et al. J Am Soc Nephrol. 2017;28(4):1229-1239. DOI: 10.1681/ASN.2016050541 |
| Birk et al. 2013 | Rat | SS-31 improved cardiac function during ischemia-reperfusion | Birk AV, et al. J Am Heart Assoc. 2013;2(1):e000159 |

**Lifespan data:** No published lifespan study with SS-31/elamipretide. Studies focus on organ-specific healthspan improvement.

### Clinical Trial Status (as of early 2025)

| NCT Number | Phase | Condition | Status | Key Details |
|------------|-------|-----------|--------|-------------|
| NCT02814097 | Phase 2 (TAZPOWER) | Primary mitochondrial myopathy (PMM) | Completed | Elamipretide SC 40mg daily; improved 6-min walk test in PMM patients |
| NCT03323749 | Phase 3 (ReCOVER) | PMM | Completed | **Did not meet primary endpoint** (6-min walk test improvement did not reach significance vs. placebo) |
| NCT02914665 | Phase 2 | Heart failure (HFrEF) | Completed | Elamipretide improved LV volumes in HFrEF patients; published |
| NCT02788747 | Phase 2 | Barth syndrome | Completed | Improvements in cardiac and muscle function |
| NCT02245620 | Phase 2 (EMBRACE) | Reperfusion injury (MI) | Completed | Did not meet primary endpoint; elamipretide did not reduce infarct size vs. placebo in STEMI patients |
| NCT03098797 | Phase 2 | Age-related macular degeneration (dry AMD) | Completed | Elamipretide (subcutaneous) showed some improvement in low-luminance visual acuity; mixed results |
| NCT05162768 | Phase 3 [VERIFY] | Geographic atrophy (dry AMD) | Active [VERIFY] | Following up on Phase 2 AMD results |

**Key 2023-2025 developments:**

- **Phase 3 ReCOVER failure (PMM):** The Phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoint, which was a significant setback for Stealth BioTherapeutics. The company's stock declined substantially.
  - However, some secondary endpoints showed trends toward improvement
  - The PMM population is heterogeneous, making trial design challenging
  - Some subset analyses suggested benefit in specific genetic subtypes [VERIFY]

- **Stealth BioTherapeutics reorganization:** After the Phase 3 failure, the company has undergone restructuring. Focus shifted toward ophthalmology (dry AMD/geographic atrophy) where the drug showed more promise. [VERIFY current company status]

- **Aging indication deprioritized:** Although preclinical aging data is compelling, the clinical setbacks in disease-specific indications have slowed the path toward aging-specific trials.

- **Academic aging studies continue:** Independent academic labs continue to study SS-31/elamipretide in aging models, with publications on:
  - Reversal of age-related vascular dysfunction
  - Improvement of age-related cognitive decline in mice
  - Restoration of aged immune cell function [VERIFY specific 2024 publications]

### Safety/Adverse Event Profile

- **Subcutaneous injection:** Well-tolerated in most trials
- **Common AEs:** Injection site reactions (erythema, pruritus, pain -- most common AE at ~10-20%), headache, nausea
- **No significant organ toxicity** reported across Phase 1-3 trials
- **No immunosuppression**
- **Cardiac safety:** No QTc prolongation or proarrhythmic signals
- Generally favorable safety profile; the issue is efficacy, not safety

### Key Publications

1. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. *Aging Cell*. 2013;12(5):763-771. DOI: 10.1111/acel.12097
2. Campbell MD, Duan J, Samber AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. *Free Radic Biol Med*. 2019;134:268-281. DOI: 10.1016/j.freeradbiomed.2018.12.031
3. Sweetwyne MT, Pippin JW, Eng DG, et al. The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. *Kidney Int*. 2017;91(5):1126-1145. DOI: 10.1016/j.kint.2016.10.036

### Controversies

- **Phase 3 failure dampened enthusiasm:** The ReCOVER trial failure raised questions about whether preclinical mitochondrial benefits translate clinically
- **Route of administration:** Subcutaneous injection daily is not ideal for a longevity intervention
- **Cost:** Elamipretide as a pharmaceutical would be expensive; not viable as a widespread longevity drug
- **Competition from UA:** Urolithin A (oral, supplement-priced, good safety) is a more accessible mitochondrial intervention

---

## 3.3 Mitochondrial Transplantation

### Overview

Mitochondrial transplantation involves harvesting healthy mitochondria from donor tissue and delivering them to cells/tissues with mitochondrial dysfunction. This emerging approach is fundamentally different from small-molecule mitochondrial therapies.

### Mechanism

1. **Isolation:** Healthy mitochondria are isolated from donor cells (typically autologous muscle tissue, placental tissue, or cultured cells) through differential centrifugation
2. **Delivery:** Isolated mitochondria are delivered via:
   - Direct tissue injection (cardiac, brain)
   - Intracoronary infusion (heart)
   - Systemic intravenous injection
   - Co-culture (in vitro)
3. **Uptake:** Recipient cells internalize exogenous mitochondria through:
   - Macropinocytosis
   - Actin-dependent endocytosis
   - Direct membrane fusion
4. **Integration:** Transplanted mitochondria integrate into the recipient cell's mitochondrial network, improving:
   - Respiratory capacity
   - ATP production
   - ROS balance
   - mtDNA integrity (if donor mitochondria have intact mtDNA)

### Key Preclinical and Early Clinical Results

| Study | Model | Key Finding | Reference |
|-------|-------|-------------|-----------|
| McCully et al. 2009 | Rabbit heart | Autologous mitochondrial transplantation improved cardiac function after ischemia | McCully JD, et al. Am J Physiol Heart Circ Physiol. 2009;296(1):H94-105 |
| Emani et al. 2017 | Human pediatric patients | First clinical use: autologous mitochondrial transplantation in 5 pediatric patients with myocardial ischemia-reperfusion injury; 4/5 showed improved ventricular function | Emani SM, et al. J Thorac Cardiovasc Surg. 2017;154(1):286-289. DOI: 10.1016/j.jtcvs.2017.01.038 |
| Shi et al. 2023 | Mouse | Mitochondrial transplantation improved cognitive function in aged mice; reduced neuroinflammation [VERIFY exact publication] | [VERIFY] |
| Nitzan et al. 2019 | Mouse (Parkinson's) | Intranasal mitochondrial delivery improved dopaminergic neuron survival in PD model | Nitzan K, et al. NPJ Parkinsons Dis. 2019 [VERIFY] |

### Aging-Specific Applications (2023-2025)

- **Concept:** Age-related mitochondrial dysfunction (accumulated mtDNA mutations, reduced ETC function, impaired dynamics) could theoretically be addressed by supplementing tissues with young, healthy mitochondria
- **Challenges for aging application:**
  - Scale: Aging affects all tissues; local transplantation cannot scale
  - Duration: Transplanted mitochondria eventually age too; repeated treatments needed
  - Source: Where to obtain sufficient healthy mitochondria for systemic treatment
  - Safety: Immune reactions to allogeneic mitochondria; unknown long-term effects
  - Quality control: Standardizing mitochondrial preparations is extremely difficult

- **Companies exploring mitochondrial transplantation:**
  - **Cellvie:** Developing mitochondrial transplantation platforms [VERIFY current status]
  - **Minovia Therapeutics:** Focused on mitochondrial augmentation therapy (MAT) for mitochondrial diseases
  - **United Therapeutics:** Exploring mitochondrial transplantation for lung diseases

### Clinical Trial Status

- **No aging-specific mitochondrial transplantation trials** registered as of early 2025
- Clinical use limited to cardiac ischemia-reperfusion (compassionate use/small studies)
- The technology remains early-stage for aging applications
- NCT numbers for cardiac mitochondrial transplantation: [VERIFY specific NCTs]

### Safety Considerations

- **Autologous transplant:** Lower immune risk but requires tissue harvest procedure
- **Allogeneic transplant:** Mitochondria have unique lipid membranes that may trigger immune responses; mtDNA can activate cGAS-STING innate immunity
- **Quality concerns:** Mitochondria are fragile; isolation and storage can damage them
- **Tumorigenesis:** Theoretical concern that introducing healthy mitochondria into pre-malignant cells could support tumor growth [VERIFY]
- **Very limited human safety data** (only cardiac case series)

### Key Publications

1. McCully JD, Cowan DB, Emani SM, Del Nido PJ. Mitochondrial transplantation: From animal models to clinical use in humans. *Mitochondrion*. 2017;34:127-134. DOI: 10.1016/j.mito.2017.03.004
2. Emani SM, Piekarski BL, Harrild D, et al. Autologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury. *J Thorac Cardiovasc Surg*. 2017;154(1):286-289. DOI: 10.1016/j.jtcvs.2017.01.038
3. Bertero E, Maack C, O'Rourke B. Mitochondrial transplantation in humans: "magical" cure or cause for concern? *J Clin Invest*. 2018;128(12):5191-5198. DOI: 10.1172/JCI124944

---

*Document compiled: February 2025*
*Data currency: Through May 2025 training data*
